Table 3.

Hemolytic activity of the APLs and pro-APLs (200 μM) upon incubation with sheep RBC for 24 h at 37°C.

Compound	HA200 (%)
	1 h	24 h
Miltefosine	90.8 ± 1.5	n.d.
M12	13.1 ± 1.0	63.9 ± 8.1
ME12	18.0 ± 1.2	103.2 ± 3.6
M${}_{{\text{E}}^{\prime }12}$	n.d.	101.7 ± 1.8
MC12	6.0 ± 1.4	59.7 ± 5.4
M${}_{{\text{C}}^{\prime }12}$	21.5 ± 2.3	70.8 ± 4.4
MC18:1	1.3 ± 1.2	12.5 ± 2.8
Perifosine	85.1 ± 4.0	n.d.
P12	8.1 ± 0.9	35.7 ± 4.1
PE12	7.1 ± 0.9	20.6 ± 5.9
P${}_{{\text{E}}^{\prime }12}$	n.d.	80.1 ± 0.2
PC12	< 1	60.7 ± 2.2
P${}_{{\text{C}}^{\prime }12}$	< 1	24.4 ± 7.6
PC18:1	n.d.	n.d.
Erufosine	84.9 ± 4.5	n.d.
E12	1.9 ± 0.7	12.0 ± 1.9
EE12	< 1	18.6 ± 1.5
E${}_{{\text{E}}^{\prime }12}$	n.d.	25.3 ± 2.6
EC12	< 1	9.6 ± 2.3
E${}_{{\text{C}}^{\prime }12}$	< 1	7.3 ± 0.8
EC18:1	< 1	20.9 ± 2.5

Data for erufosine and erufosine prodrugs are reported from the literature (Gaillard et al., 2019). n.d.: not determined.